Key result
Adjunctive therapy with abciximab during carotid stenting in 45 patients resulted in no periprocedural strokes, myocardial infarctions, or neurological deaths.
Why the study?
Does abciximab as adjunctive therapy in carotid stenting improve procedural success and clinical outcomes in patients with symptomatic critical carotid lesions?
Observational (n=45)
Does abciximab as adjunctive therapy in carotid stenting improve procedural success and clinical outcomes in patients with symptomatic critical carotid lesions?
Abciximab as adjunctive therapy during carotid stenting was associated with no periprocedural neurological events, though some bleeding and late MIs occurred.
Answers are grounded in this paper and cite their sources.
Provides preliminary support for abciximab in carotid stenting; hypothesis-generating and requires randomized confirmation before practice change.
We evaluated the use of abciximab (ReoPro), a monoclonal glycoprotein (GP) IIb/IIIa inhibitor, in 45 patients and 49 carotid vessels undergoing stent placement for neurologically symptomatic, critical lesions of the common and/or internal carotid arteries. Our assessments included procedural success and clinical outcomes including stroke, myocardial infarction (MI), neurological death, and bleeding. There were no instances of minor or major stroke, Q‐wave or non‐Q‐wave MI, thrombocytopenia, or neurological death in the periprocedural in‐hospital period immediately poststenting to discharge, nor any neurological events related to the ipsilateral hemisphere or neurological death during follow‐up of up to 1 year, 6 months, and 30 days (30,10, and 5 patients, respectively). The hemoglnbin/hematocrit levels dropped in two patients, necessitating blood transfusions. Two patients died with multiple organ failure, and three more developed a non‐Q‐wave infarction at 4 months, 2 months, and 3 weeks poststenting, respectively.
No takes yet. Share an insight, caveat, or question.
Ceceña et al. (1999) conducted an observational in Neurologically symptomatic, critical lesions of the common and/or internal carotid arteries (n=45). Abciximab was evaluated on Procedural success and clinical outcomes including stroke, myocardial infarction, neurological death, and bleeding. Adjunctive therapy with abciximab during carotid stenting in 45 patients resulted in no periprocedural strokes, myocardial infarctions, or neurological deaths.
Synapse has enriched 10 related papers. Consider them for comparative context: